ImmunityBio, Inc., previously known as NantKwest, is a late-stage immunotherapy company with a focus on harnessing the body’s natural killer (NK) cells to fight cancer, infectious diseases, and other health threats. The company is listed on the NASDAQ exchange under the ticker symbol IBRX.
ImmunityBio has a remarkable profile primarily because of its pioneering work in NK cell-based therapies. The company's approach is pivoted on the science of harnessing the power of the immune system by unleashing the potential of NK cells. These are a critical subset of the body's immune cells, which innately guard against cancer and a broad range of other diseases. NK cells - innate in their nature - have a built-in mechanism to identify and kill mutated cells, making them uniquely suited for the task of combating complex diseases.
The company’s innovative therapies include an array of patented technologies, such as cytokine-based immunotherapies and next-generation adeno-associated virus (AAV) delivery platforms. ImmunityBio's portfolio features both autologous and allogeneic cell therapies, with a specific concentration on the latter due to their “off-the-shelf” applicability. This allows for broad-scale production and deployment of therapies, ensuring patients receive needed treatment swiftly.
The company’s work extends beyond cancer, as ImmunityBio has been approved to test certain therapies to combat the ongoing COVID-19 crisis. Their primary drug candidate, Anktiva, has shown promising potential in early stage trial results, making ImmunityBio a significant player in responding to critical healthcare threats globally.
ImmunityBio was founded by Dr. Patrick Soon-Shiong, a surgeon, and scientist, who is often referred to as the world’s richest doctor. Dr. Soon-Shiong also acts as Chairman and CEO of the company, leveraging his substantial experience in the healthcare sector to guide the firm's novel approaches and innovative healthcare solutions.
The company’s headquarters are located in Culver City, California. It also maintains research, development, and manufacturing facilities in California, Maryland, and Massachusetts, reflecting a broad geographical footprint and a comprehensive, integrated approach to healthcare solutions.
Highly dedicated to making a difference in patient lives by combating challenging diseases with innovative immunotherapies, ImmunityBio, Inc. is undoubtedly contributing substantially to the global biotech industry. With a robust pipeline and an evolving portfolio of therapeutics, ImmunityBio is an intriguing entity in the landscape of immunotherapy and a name to watch in the future progression of the field.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
ImmunityBio (IBRX) shares surged by nearly 10% after its founder, Dr. Patrick Soon-Shiong, met with Turkish President Recep Tayyip Erdogan, indicating progress on the company's expansion into Turkey. This development follows the FDA approval of ImmunityBio's immunotherapy drug Anktiva, which has already been accepted in 34 countries and significantly boosted the company's Q2 revenues. Institutional investors are also bullish on IBRX, increasing their combined holdings by over 62% in the last quarter.
ImmunityBio Inc. (IBRX) shares jumped 9.94% after its founder, Dr. Patrick Soon-Shiong, met with Turkish President Recep Tayyip Erdogan, sparking optimism about the company's planned expansion into Turkey. This expansion follows the FDA approval and international acceptance of its immunotherapy drug Anktiva in 34 countries. The company also reported strong Q2 revenues, nearly doubling year-over-year, and increased institutional investor conviction.
ImmunityBio (IBRX) shares saw a significant jump after founder Patrick Soon-Shiong teased Nant's upcoming launch of blockchain and tokenized stocks, following the SEC's new "Innovation Exemption." This has led to retail speculation that IBRX shares could be tokenized, with traders discussing the potential impact on short sellers and the efficiency of capital markets. Nant Global Finance is actively building a blockchain-enabled capital-markets platform, integrating various capabilities through acquisitions.
PDS Biotech announced the initial closing of a PIPE financing, raising $11.3 million, led by Nant Capital. The financing aims to fund clinical programs and advance PDS0301 into late-stage development. Additionally, Dr. Patrick Soon-Shiong and James Banaag have been appointed to the company's board of directors.